UCB disclosed plans to acquire clinical-stage epilepsy developer Neurona Therapeutics for $650 million, with potential milestone payments up to $500 million. The move is intended to broaden UCB’s clinical-stage epilepsy portfolio as the company looks to reinforce its pipeline with assets at a more advanced development stage. Neurona’s program is described as a treatment in epilepsy, positioning the acquisition as a step toward expanding therapeutic options for patients with seizure disorders. The structure also signals UCB’s willingness to pay for differentiated mechanisms or clearer clinical differentiation. For biotech watchers, the headline is portfolio reinforcement: acquisitions like this often determine near- to mid-term trial throughput and what registrational timelines UCB can credibly target next.